期刊文献+

高效液相色谱法测定人血浆3-氯酪氨酸浓度 被引量:1

Determination of 3-chlorotyrosine concentration in human plasma by HPLC with electrochemical detection
原文传递
导出
摘要 目的建立人血浆3-氯酪氨酸(3-CT)浓度的定量分析方法。方法用三氯乙酸沉淀血浆蛋白后,HPLC—ECD定量检测。结果3.氯酪氨酸血浆标准曲线的线性范围为0.0625—2.000μmol·L^-1,r〉0.9966,回收率〉71.8%。日内和日间的精密度(RSD%)分别〈8.8%和11.1%。3-氯酪氨酸的保留时间为(16.57±0.30)min,总分析时间32min。测得健康人和尿毒症患者(各6例)血浆3-CT浓度分别为(0.16±0.13)和(2.47±0.73)μmol·L^-1(P〈0.01)。结论本法所需样本量低,预处理步骤简便,适用于临床进行氧化应激、治疗、预后、诊断等研究工作之需。 AIM To develop a quantitative analysis method for the determination of 3-chlomtyrosine (3-CT) in human plasma. METHODS 3-CT in plasma was detennined using reversed-phase HPLC with electrochemical detection after precipitation all of the plasma proteins with trichloroacetic acid. RESULTS The linearity of the method was in the range of 0.062 5 to 2.000 μmol·L^- 1 for 3-CT with a correlation coefficient of more than 0. 996 6. Over 71.8% of the recovery of 3-CT in plasma was obtained. The relative standard deviation(RSD) of the method was less than 8.8% for within-day and 11.1% for between-day, respectively. The average retention time for 3-CT was ( 16.57 ± 0.30)rain. A single run for the measurement of 3-CT was 32 min. The average levels for measured 3-CT were (0.16 ± 0.13)μmol· L^- 1 for healthy population ( n = 6) and (2.47 ± 0.73) μmol· L- 1 for uremic patients ( n = 6), respectively ( P 〈 0.01 ). CONCLUSION The presented method is reliable and simple,and is applicable to those areas such as diagnosis, treatment and prognosis in clinic as well as the research work on oxidative stress and related diseases.
出处 《中国临床药学杂志》 CAS 2009年第4期213-216,共4页 Chinese Journal of Clinical Pharmacy
基金 国家自然科学基金(30300160)
关键词 高效液相色谱 3-氯酪氨酸 氧化应激 电化学检测 HPLC 3-chlorotyrosine oxidative stress electrochemical detection HPLC 3-chlorotyrosine oxidative stress electrochemical detection
  • 相关文献

参考文献6

  • 1Becket BN, Himmelfarb J, Henrieh WL, et al. Reassessing the cardiac risk profile in chronic hemodialysis patients: a hypahesis on the role of oxidant stress and other non-traditional cardiac risk faotors[J]. J Am Soc Nephrol, 1997,8(3) :475.
  • 2Boaz M, Smetana S, Weinstein, T, et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE) : randomised placebo-controlled trial [ J ]. Lancet, 2000, 356 (9237) : 1213.
  • 3Carr AC, McCall MR, Frei B. Oxidation of LDL by myeloperoxidase and reactive nitrogen species: reaction pathways and antioxidant protection [J]. Artefioscler Thromb Vase Biol,2000,20(7) : 1716.
  • 4Pietzseh J, Kopprasch S, Bergrnann R. Analysis of 3-chlorotyrosine as a specific marker of protein oxidation: the use of N(O,S)-ethoxycarbonyl- trifluoroethyl ester derivatives and gas chromatography/mass spectrometry [J]. Rapid Commun Mass Spectrom,2003,17(8) :767.
  • 5Cheng ML, Chen CM, Gu PW, et al. Elevated levels of myeloperoxidase, white blood cell count and 3-chlomtyrosine in Taiwan Residents patients with acute myocardial infarction [ J ], Clin Biochem, 2008,41 (7 - 8) : 554.
  • 6Gaut JP, Byun J,Tran HD, et al. Artifact-free quantification of free 3- ehlorotyrosine, 3-bromotyrosine, and 3-nitrotyrosine in human plasma by electron capture-negative chemical ionization gas chromatography mass spectrometry and liquid chromatography-electrospray ionization tandem mass spectrometry[J]. Anal Biochem,2002,300(2) :252.

同被引文献1

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部